Albatroz Therapeutics

AMGEN AND NSG BIOLABS ANNOUNCE ALBATROZ THERAPEUTICS AS WINNER OF FIRST AMGEN GOLDEN TICKET IN SINGAPORE

19/3/2023

The Golden Ticket will help to boost the biotech startup's capabilities and to develop further the emerging biotech ecosystem in Southeast Asia.

SINGAPORE, March 19, 2023 -- Leading global biotechnology company Amgen and NSG BioLabs, Singapore's largest and leading provider of biotechnology (biotech) co-working laboratories and offices, announced Albatroz Therapeutics as the winner of the first Amgen Golden Ticket in Singapore. Albatroz Therapeutics will be rewarded a one-year free residency in NSG Biolabs' fully-equipped, turnkey, and certified BSL-2 laboratory, as well as additional facility benefits and connections to Amgen's scientific and business leaders.

ALBATROZ THERAPEUTICS FEATURED IN A * STAR RESEARCH HIGHLIGHTS

6/4/2021

The solid cancer targeting technology of Albatroz Therapeutics has been featured in A * STAR Research Highlights.
The therapeutic approach is based on the novel discovery by the A * STAR lab of Abatroz's scientific founder Dr. Frederic Bard that glycosylation-driven extracellular matrix degradation is essential for tumor growth.

ALBATROZ THERAPEUTICS SELECTED AS A FINALIST IN THE 2020 BRACE AWARD VENTURE COMPETITION

11/11/2020

Albatroz Therapeutics is proud to be selected as one of the two finalists in the 2020 BRACE Award Venture Competition.
BRACE (Bridging Research from Academia to Cancer Entrepreneurship), an initiative by The Asian Fund for Cancer Research (AFCR), is designed to advance and catalyze the commercialization of innovative cancer research discoveries. BRACE Award Venture Competitions are conducted throughout Asia, and candidates are selected and semi-finalists are judged by some of the most respected minds in the cancer research, investment and business fields.
The winner, selected from the two finalists, will receive up to the equivalent of HK $ 2,000,000 in investment funding from AFCR.